-- Scott Roberts
MONDAY, March 25 (HealthDay News) -- The TOBI Podhaler
(tobramycin inhalation powder) has been approved by the U.S. Food
and Drug Administration to treat cystic fibrosis patients infected
Pseudomonas aeruginosa, a bacterium that can damage the
Cystic fibrosis, affecting about 30,000 people in the United
States, causes production of thick, sticky mucus that builds up in
the lungs. This can lead to chronic bacterial infections, the FDA
said in a news release.
The TOBI Podhaler, used twice daily, was evaluated in clinical
trials involving 95 adults and children six years and older with
cystic fibrosis. The most common side effects included cough,
coughing up blood, shortness of breath, fever, mouth and throat
pain, changes in voice and headache.
The antibiotic inhaler is marketed by Novartis, based in East
Medline Plus has more about
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.